A global comparison of the cost of patented cancer drugs in relation to global differences in wealth

Oncotarget

Volumn 8, Issue 42, 2017, Pages 71548-71555

  Goldstein, Daniel A ^a,b   Clark, Jonathon ^a   Tu, Yifan ^c   Zhang, Jie ^d   Fang, Fenqi ^d   Goldstein, Robert ^e   Stemmer, Salomon M ^a,f   Rosenbaum, Eli ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b EMORY UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cost, affordability

Indexed keywords

EID: 85032263232     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17742     Document Type: Article

References (30)

1. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the Market for Anticancer Drugs. J Econ Perspect. 2015; 29:139–62. https://doi.org/10.1257/jep.29.1.139.
2. Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol. 2015; 33:1112–18. https://doi.org/10.1200/JCO.2014.58.4904.
3. Durkee BY, Qian Y, Pollom EL, King MT, Dudley SA, Shaffer JL, Chang DT, Gibbs IC, Goldhaber-Fiebert JD, Horst KC. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2016; 34:902–09. https://doi.org/10.1200/JCO.2015.62.9105.
4. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, et al, and American Society of Clinical Oncology. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015; 33:2563–77. https://doi.org/10.1200/JCO.2015.61.6706.
5. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015; 26:1547–73. https://doi.org/10.1093/annonc/ mdv249.
6. Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, Newcomb P, Hollingworth W, Overstreet K. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013; 32:1143–52. https://doi.org/10.1377/hlthaff.2012.1263.
7. Vogler S, Vitry A, Babar ZU. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016; 17:39–47. https://doi.org/10.1016/S1470-2045(15)00449-0.
8. Kantarjian H, Mathisen MS, Lipton JH. Having “Skin in the Game” and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs. JAMA Oncol. 2015; 1:729–30. https://doi.org/10.1001/jamaoncol.2015.1024.
9. FDA Approved Drugs. 12 Dec 2015. http://www.centerwatch.com/drug-information/fda-approved-drugs/.
10. The Pharmaceutical Benefits Scheme. 12 Dec 2015. http://www.pbs.gov.au/browse/medicine-listing.
11. Chinese Government Pharmacy Information Website. 18 Dec 2015. http://www.cpi.gov.cn/publish/default/.
12. DrugsUpdate.com. 18 Dec 2015. http://www.drugsupdate. com.
13. Medline India. 18 Dec 2015. http://www.medlineindia.com.
14. Israel Ministry of Health. 18 Dec 2015. http://www.health.gov.il/Subjects/Finance/DrugPrice/Pages/default.aspx.
15. Medicine Price Registry. 18 Dec 2015. https://mpr.code4sa. org.
16. British National Formulary. 18 Mar 2016. http://www.bnf. org.
17. Average Wholesale Price. 18 Dec 2015. http://www.uptodate.com.
18. Exchnge Rates UK. 18 Mar 2016. http://www.exchangerates.org.uk/historical/USD/19_01_2016.
19. Purchasing Power Parities and the Real Size of World Economies – A Comprehensive Report of the 2011 International Comparison Program. Washington, DC: World Bank Group; 2015. https://doi.org/10.1596/978-1-4648-0329-1.
20. Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, Augustovski F, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report-Part VI. Value Health. 2010; 13:28–33. https://doi.org/10.1111/j.1524-4733.2009.00662.x.
21. World Economic Outlook Database. 2015. 23 Jan 2016. http://www.imf.org/external/pubs/ft/weo/2016/01/weodata/index.aspx.
22. Average Salaries around the world. 23 Jan 2016. http://www.statista.com/statistics/226956/average-world-wagesin-purchasing-power-parity-dollars/.
23. Glivec International Patient Assistance Program. 6 Sep 2016. https://themaxfoundation.org/GIPAP.
24. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26:2013–19. https://doi.org/10.1200/JCO.2007.14.9930.
25. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344:1031–37. https://doi.org/10.1056/NEJM200104053441401.
26. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, et al, and Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659–72. https:// doi.org/10.1056/NEJMoa052306.
27. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014; 32:1277–80. https://doi.org/10.1200/JCO.2013.53.8009.
28. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med. 2016; 176:65–73. https://doi.org/10.1001/ jamainternmed.2015.6011.
29. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med. 2016; 13:e1002032. https://doi.org/10.1371/journal.pmed.1002032.
30. Berwick D. “We all have AIDS”: case for reducing the cost of HIV drugs to zero. BMJ. 2002; 324:214–16. https://doi.org/10.1136/bmj.324.7331.214.